Keywords: mechanism, action, proposed, ribi, mpl-c, immunochem, new
Mechanism Of Action Proposed For Ribi's MPL-C
Article | 20 November 1995
Ribi ImmunoChem's new immunomodulator, MPL-C, significantly reduces cardiac infarct size when given prior to a myocardial infarction, according to preclinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
